{"entity":{"id":"da-tech-anti-amyloid-mab","kind":"technology","name":"Anti-amyloid antibodies","aka":[],"tldr":"Infused antibodies can lower amyloid in early Alzheimer’s disease. They need monitoring for brain swelling or bleeding on MRI.","summary":"Lecanemab and donanemab are approved examples in the US for early symptomatic disease after amyloid confirmation. Aducanumab’s Alzheimer’s indication was withdrawn.","asOf":"2026-09-21","links":[{"label":"FDA Leqembi","url":"https://www.fda.gov/news-events/press-announcements/fda-converts-novel-alzheimers-disease-treatment-traditional-approval"}],"tags":["dementia-atlas"],"related":[],"cancers":[],"sections":["da-front-anti-amyloid"],"technologies":[],"targets":[],"drugs":["da-lecanemab","da-donanemab","da-aducanumab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"principle":"Monoclonal antibodies bind aggregated amyloid and promote clearance, with ARIA as a key risk.","strengths":[],"limitations":[]},"route":"/technologies/da-tech-anti-amyloid-mab/","neighbours":{"section":[{"id":"da-front-anti-amyloid","kind":"section","name":"Anti-amyloid treatment","route":"/fronts/da-front-anti-amyloid/"}],"drug":[{"id":"da-aducanumab","kind":"drug","name":"Aducanumab","route":"/drugs/da-aducanumab/"},{"id":"da-donanemab","kind":"drug","name":"Donanemab","route":"/drugs/da-donanemab/"},{"id":"da-lecanemab","kind":"drug","name":"Lecanemab","route":"/drugs/da-lecanemab/"}],"cancer":[{"id":"alzheimers-disease","kind":"cancer","name":"Alzheimer’s disease","route":"/diagnoses/alzheimers-disease/"}]}}